BGM
LRMR icon

Burkehill Global Management’s Larimar Therapeutics LRMR Stock Holding History

Burkehill Global Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$915K Hold
300,000
– – 0.03% 156
2026
Q1 		$1.35M Buy
+300,000
New +$1.2M 0.07% 149

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Burkehill Global Management's LRMR Position: Q2 2026 in Review

Burkehill Global Management held its Larimar Therapeutics (LRMR) position steady in Q2 2026 at 300,000 shares worth $915K. The position accounts for 0.03% of the portfolio, ranked #156.

Burkehill Global Management first reported a position in LRMR in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.35M in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Burkehill Global Management held 300,000 shares of Larimar Therapeutics worth $915K as of Q2 2026.
  • Burkehill Global Management left its Larimar Therapeutics share count unchanged in Q2 2026.
  • Larimar Therapeutics made up 0.03% of Burkehill Global Management's portfolio in Q2 2026, its #156 holding.
  • Burkehill Global Management first reported a position in Larimar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Burkehill Global Management's Larimar Therapeutics position peaked at $1.35M in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Burkehill Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.